The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05033964

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05033964
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Brazil, Czechia, Netherlands, New Zealand (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05033964. Randomized; single masking; primary purpose treatment. Start 2021-12-15 (actual); primary completion 2022-12-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
Intervention (Combination product)
Percutaneous Coronary Intervention with drug eluting stents
Lead sponsor
Elixir Medical Corporation (class: industry)

Record details

Record id
cardio:ct-nct05033964
Content hash
a8122b74620c75e264d8edfca692f117419df217ec34208a2dbd54f9c5eccc93